What Is Coronary Artery Calcium Score

A coronary artery calcium (CAC) score quantifies the amount of calcified atherosclerotic plaque in the coronary arteries using a non-contrast CT scan. The result is expressed as an Agatston score, a number derived from the density and area of calcium deposits detected across all coronary segments. It serves as a direct anatomical marker of coronary atherosclerosis, distinct from blood-based risk factors that estimate disease probability indirectly.

Cardiovascular disease remains the leading cause of death globally, yet standard risk calculators built on blood pressure, cholesterol, and smoking status frequently misclassify individuals. Many heart attacks occur in people categorized as low or intermediate risk. The CAC score closes this gap by measuring the disease itself rather than its upstream drivers. A person with textbook-normal cholesterol can still harbor substantial coronary plaque, and the CAC scan reveals that burden directly.

From a longevity perspective, the CAC score offers an unusually clear signal. A score of zero in a middle-aged adult confers what researchers sometimes call a "warranty period" of very low cardiac event risk spanning five to ten years. Conversely, a high score in an otherwise healthy-seeming individual can trigger meaningful changes in therapy and behavior years before symptoms appear. Because atherosclerosis develops over decades, early detection through a CAC scan provides a wide window for intervention during the period when plaque progression can still be slowed substantially.

During a CAC scan, an electrocardiogram-gated CT acquires thin-slice images of the heart without contrast dye. The gating synchronizes image capture to the diastolic phase of the cardiac cycle, when the heart is relatively still, producing sharper images of the coronary tree. Software then identifies any voxel above a Hounsfield unit threshold of 130, marking it as calcified tissue. Each calcified lesion is scored based on its area and peak density, and the individual lesion scores are summed to produce the total Agatston score.

The Agatston scoring system, developed in the late 1980s, assigns density weighting factors of 1 through 4 corresponding to increasing Hounsfield unit ranges. A larger or denser deposit scores higher. Because the method is standardized, scores are comparable across different scanners and facilities, though some variation exists between scanner generations. The total score is then interpreted against population percentiles stratified by age, sex, and ethnicity, because a score of 100 carries different implications for a 45-year-old than for a 75-year-old.

Calcification represents a late stage in atherosclerotic plaque development. Plaque begins as fatty streaks in the arterial intima, progresses through inflammatory remodeling, and eventually deposits calcium within its fibrous cap and necrotic core. The presence of calcium therefore signals that the atherosclerotic process has been active for years or decades. While the CAC score does not detect soft or non-calcified plaque, the correlation between calcified and total plaque burden is strong in population studies, making the score a reliable proxy for overall coronary disease load.

The CAC scan measures calcified plaque deposits within the walls of the coronary arteries. It does not assess blood flow, plaque stability, or the presence of soft (non-calcified) plaque. The output is a single number, the Agatston score, which integrates both the volume and density of all detected calcium across the left main, left anterior descending, circumflex, and right coronary arteries. Individual vessel scores are also reported, which can indicate whether disease is focal or diffuse.

Because calcium deposition is a downstream consequence of years of active atherosclerosis, the score reflects cumulative plaque burden rather than current disease activity. Two individuals with the same score may have arrived there by different trajectories: one through rapid recent progression, the other through slow accumulation over decades. This distinction matters clinically and is one reason serial testing can add value beyond a single measurement.

Preparation for a CAC scan is minimal. No fasting is required, and no intravenous contrast dye is used. You should avoid caffeine for four to six hours before the scan, as elevated heart rate degrades image quality. Wear comfortable clothing without metal zippers or snaps near the chest, as metallic objects can produce artifacts.

The scan itself takes approximately five to ten minutes. You will lie on a CT table, and electrodes will be placed on your chest to synchronize image acquisition with your cardiac rhythm. You may be asked to hold your breath briefly during the scan. There is no recovery period; you can resume normal activities immediately.

Results are reported as a total Agatston score with the following commonly used categories: a score of 0 means no identifiable calcified plaque; 1 to 99 indicates mild plaque; 100 to 399 indicates moderate plaque; and 400 or above indicates extensive calcified disease. These raw numbers are then compared to age, sex, and ethnicity-matched reference populations to generate a percentile rank. Being in the 75th percentile or higher for your demographic group signals disproportionate plaque burden relative to peers.

The clinical interpretation depends heavily on context. A 50-year-old with a score of 150 faces a different risk profile than a 70-year-old with the same number, because the percentile rank differs dramatically. A zero score provides strong reassurance of low near-term risk, but does not eliminate the need for ongoing risk-factor management. Any non-zero result should prompt a conversation about lipid-lowering therapy, blood pressure optimization, and lifestyle strategies. If sequential scans are obtained, the rate of score progression (often expressed as Agatston units per year) provides additional insight into whether interventions are adequately slowing disease advancement.

There is no firm consensus on repeat testing intervals, and guidelines vary. For someone with an initial score of zero, repeating the scan in five to ten years is reasonable if risk factors remain stable or if new risk factors emerge. A baseline score above zero may warrant a follow-up scan in three to five years to assess progression rate, particularly if the result influenced a treatment decision.

Frequent rescanning (annually, for instance) is generally not recommended because the incremental information gain is small relative to cumulative radiation exposure and cost. The score tends to increase over time in most people simply due to aging, so the relevant question is whether it is increasing faster than expected. Tracking progression is most useful when paired with concurrent changes in therapy, such as statin initiation or intensified metabolic management, to evaluate whether the intervention is modifying disease trajectory.

The evidence base for the CAC score is large and well established. The Multi-Ethnic Study of Atherosclerosis (MESA), a prospective cohort of over 6,000 adults followed for more than 15 years, has been a primary source of data linking CAC scores to cardiovascular event rates across racial and ethnic groups. Multiple large observational studies have consistently demonstrated that a CAC score of zero is associated with very low ten-year event rates (generally below 1 to 2 percent for major cardiac events), while high scores correlate with significantly elevated risk independent of traditional risk factors.

Guideline bodies have incorporated CAC scoring into clinical recommendations. The 2018 American Heart Association and American College of Cardiology cholesterol guidelines endorse CAC testing as a "tie-breaker" for intermediate-risk adults when the decision to start statin therapy is uncertain. However, the test has limitations. It does not detect non-calcified (soft) plaque, cannot assess plaque vulnerability, and provides no information about stenosis severity. Randomized controlled trial evidence directly demonstrating that CAC-guided therapy reduces hard endpoints like heart attack or death, compared to standard risk-factor-based management, remains limited. The test's value is supported primarily by strong and consistent observational and cohort data rather than large randomized trials.

Radiation exposure from a CAC scan is low, roughly 1 millisievert, comparable to several months of natural background radiation. The primary risk is downstream: an incidental finding on the scan (such as a lung nodule) can trigger additional imaging or procedures with their own costs and radiation burden. A non-zero score may cause anxiety, and clinicians sometimes initiate medications based on a single elevated number without adequate context. Statin initiation after a high score is common and generally supported by guidelines, but the decision should account for the full clinical picture. The scan is not appropriate for individuals already diagnosed with coronary artery disease, as their treatment trajectory is already determined, nor for very young or very low-risk adults in whom the probability of detectable calcium is negligible.